Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

DJ927

Known as: DJ 927, DJ-927 
A semi-synthetic orally-available taxane derivative with potent antineoplastic properties. DJ-927 binds to tubulin, promoting microtubule assembly… Expand
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tesetaxel

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung Cancer
Introduction: A phase I/II study was performed to assess the efficacy and toxicity of a new oral taxane in patients with… Expand
Review
2006
Review
2006
Update on tubulin-binding agents.
The clinical and commercial success of the taxanes and vinca alkaloids resulted in a drive to improve on current formulations and… Expand
2006
2006
Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer.
3591 Background: DJ-927, a novel oral tubulin depolymerization inhibitor, causes apoptosis and DNA cell division arrest. It is… Expand
2006
2006
A phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen.
4081 Background: Most 1st-line combination chemotherapy regimens in pts with advanced GC include 5-FU. Taxanes are also active… Expand
2006
2006
A phase II study of DJ-927 administered orally once every three weeks as second line therapy to subjects with locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of…
17006 Background: For the treatment of NSCLC (1st and 2nd line) effective oral formulations of drugs are currently investigated… Expand
2006
2006
641 POSTER Effecacy and prediction of response to the new oral taxane DJ-927 in anthacycline pre-treated advanced breast cancer (ABC)
 
2005
2005
Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses
 
2004
2004
Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers.
2028 Background: DJ-927, a novel semi-synthetic taxane and a poor substrate of P-glycoprotein (Pgp), is orally bioavailable and… Expand
2004
2004
Absorption, distribution, and excretion of DJ-927, a novel orally effective taxane, in mice, dogs, and monkeys.
DJ-927, currently undergoing Phase I clinical trial, is a new orally effective taxane with potent antitumor effects. The… Expand
  • figure 2
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2003
Highly Cited
2003
DJ‐927, a novel oral taxane, overcomes P‐glycoprotein‐mediated multidrug resistance in vitro and in vivo
DJ‐927 is a novel taxane, which was selected for high solubility, non‐neurotoxicity, oral bioavailability, and potent antitumor… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE